- Home
- SOUNW vs BIOA Comparison
SOUNW vs BIOA Comparison
Compare SOUNW & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOUNW
- BIOA
- Stock Information
- Founded
- SOUNW N/A
- BIOA 2015
- Country
- SOUNW United States
- BIOA United States
- Employees
- SOUNW 260
- BIOA N/A
- Industry
- SOUNW EDP Services
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- SOUNW Technology
- BIOA Health Care
- Exchange
- SOUNW Nasdaq
- BIOA Nasdaq
- Market Cap
- SOUNW N/A
- BIOA 207.6M
- IPO Year
- SOUNW 2021
- BIOA 2024
- Fundamental
- Price
- SOUNW $11.52
- BIOA $5.82
- Analyst Decision
- SOUNW
- BIOA Hold
- Analyst Count
- SOUNW 0
- BIOA 3
- Target Price
- SOUNW N/A
- BIOA $18.00
- AVG Volume (30 Days)
- SOUNW N/A
- BIOA 1.7M
- Earning Date
- SOUNW N/A
- BIOA 02-15-2025
- Dividend Yield
- SOUNW N/A
- BIOA N/A
- EPS Growth
- SOUNW N/A
- BIOA N/A
- EPS
- SOUNW N/A
- BIOA N/A
- Revenue
- SOUNW N/A
- BIOA N/A
- Revenue This Year
- SOUNW N/A
- BIOA N/A
- Revenue Next Year
- SOUNW N/A
- BIOA N/A
- P/E Ratio
- SOUNW N/A
- BIOA N/A
- Revenue Growth
- SOUNW N/A
- BIOA N/A
- 52 Week Low
- SOUNW N/A
- BIOA $3.85
- 52 Week High
- SOUNW N/A
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- SOUNW N/A
- BIOA N/A
- Support Level
- SOUNW N/A
- BIOA N/A
- Resistance Level
- SOUNW N/A
- BIOA N/A
- Average True Range (ATR)
- SOUNW 0.00
- BIOA 0.00
- MACD
- SOUNW 0.00
- BIOA 0.00
- Stochastic Oscillator
- SOUNW 0.00
- BIOA 0.00
About SOUNW SoundHound AI Inc. Warrant
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.